Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines

Swett-Tapia, Cindy; Bogaert, Lies; Jong, Pa de; Hoek, Vladimir van; Schouten, Theo; Damen, Irma; Spek, Dirk; Wanningen, Patrick; Radošević, Katarina; Widjojoatmodjo, Myra N.; Zahn, Roland; Custers, Jerome; Roy, Subhasish

doi:10.1099/jgv.0.000523

Cited by 10 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of paramyxoviruses have been used as vaccine vectors (Kim and Samal, 2016; Liang et al, 2016; Seki and Matano, 2016; Swett-Tapia et al, 2016). Paramyxoviruses are good vaccine vectors because they do not have a DNA phase in their life cycle and therefore do not integrate into host cell DNA.…”

Section: Discussionmentioning

confidence: 99%

“…Members of this family are primarily characterized by possessing a linear, non-segmented negative-sense (NNS) RNA genome, which encodes 6–10 viral genes tandemly (Lamb and Parks, 2013). Some paramyxoviruses, such as Sendai virus, human parainfluenza virus, and Newcastle disease virus (NDV), have been used as viral vectors in biological experiments, vaccine development and cancer therapy, and offer several advantages (Yonemitsu and Kaneda, 1999; Matveeva et al, 2015; Kim and Samal, 2016; Liang et al, 2016; Seki and Matano, 2016; Swett-Tapia et al, 2016; Yamasaki et al, 2016). First, the complete cytoplasmic replication of paramyxoviruses limits their integration into host cell genome.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene

Yoshida

Samal

2017

Front. Microbiol.

View full text Add to dashboard Cite

Avian paramyxovirus serotype 3 (APMV-3) causes infection in a wide variety of avian species, but it does not cause apparent diseases in chickens. On the contrary, APMV-1, also known as Newcastle disease virus (NDV), can cause severe disease in chickens. Currently, natural low virulence strains of NDV are used as live-attenuated vaccines throughout the world. NDV is also being evaluated as a vaccine vector against poultry pathogens. However, due to routine vaccination programs, chickens often possess pre-existing antibodies against NDV, which may cause the chickens to be less sensitive to recombinant NDV vaccines expressing antigens of other avian pathogens. Therefore, it may be possible for an APMV-3 vector vaccine to circumvent this issue. In this study, we determined the optimal insertion site in the genome of APMV-3 for high level expression of a foreign gene. We generated recombinant APMV-3 viruses expressing the green fluorescent protein (GFP) by inserting the GFP gene at five different intergenic regions in the genome. The levels of GFP transcription and translation were evaluated. Interestingly, the levels of GFP transcription and translation did not follow the 3′-to-5′ attenuation mechanism of non-segmented, negative-sense RNA viruses. The insertion of GFP gene into the P-M gene junction resulted in higher level of expression of GFP than when the gene was inserted into the upstream N-P gene junction. Unlike NDV, insertion of GFP did not attenuate the growth efficiency of AMPV-3. Thus, APMV-3 could be a more useful vaccine vector for avian pathogens than NDV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene

Yoshida

Samal

2017

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Development of a vaccine against RSV has been identified as a priority by WHO based on the large global burden, particularly in neonates and young infants [1,2]. Various MVbased RSV candidates have been developed and have been shown to protect NHP or cotton rats against challenge [34,35,[99][100][101]. Concerning viral hepatitis, the global burden is still increasing and is predominantly caused by Hepatitis B and C [1], emphasizing the need for additional measures.…”

Section: Mv-based Preclinical Candidatesmentioning

confidence: 99%

Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya

Gerke

Frantz

Ramsauer

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: The large global burden of viral infections and especially the rapidly spreading vectorborne diseases and other emerging viral diseases show the need for new approaches in vaccine development. Several new vaccine technology platforms have been developed and are under evaluation. Areas covered: This article discusses the measles vector platform technology derived from the safe and highly efficacious measles virus vaccine. The pipeline of measles-vectored vaccine candidates against viral diseases is reviewed. Particular focus is given to the Chikungunya vaccine candidate as the first measles-vectored vaccine that demonstrated safety, immunogenicity, and functionality of the technology in humans even in the presence of pre-existing anti-measles immunity and thus achieved proof of concept for the technology. Expert commentary: Demonstrating no impact of pre-existing anti-measles immunity in humans on the response to the transgene was fundamental for the technology and indicates that the technology is suitable for large-scale immunization in measles pre-immune populations. The proof of concept in humans combined with a large preclinical track record of safety, immunogenicity, and efficacy for a variety of pathogens suggest the measles vector platform as promising plug-and-play vaccine platform technology for rapid development of effective preventive vaccines against viral and other infectious diseases.

show abstract

“…Specific humoral and interferon-γ (IFN-γ) responses were observed in pigs, which were also protected against influenza virus challenges. Recombinant MV vectors carrying the HA gene have also been applied for vaccination studies [39]. Also VSV vectors have been utilized for vaccine development against influenza virus [40].…”

Section: Self-replicating Rna Virus-based Vaccinesmentioning

confidence: 99%

“…Furthermore, mice were immunized with MV vectors expressing the MERS-CoV glycoprotein, which resulted in induction of T-cell and antibody responses and protection against lethal doses of MERS-CoV [58]. Respiratory syncytial virus (RSV) has also been targeted with recombinant MV vectors by expression of the RSV fusion protein (RSV-F) [39]. Immunization of cotton rats induced neutralizing antibodies against RSV and protected against RSV infection in the lungs.…”

Section: Self-replicating Rna Virus-based Vaccinesmentioning

confidence: 99%

Replicon RNA Viral Vectors as Vaccines

Lundström¹

2016

Vaccines

View full text Add to dashboard Cite

Single-stranded RNA viruses of both positive and negative polarity have been used as vectors for vaccine development. In this context, alphaviruses, flaviviruses, measles virus and rhabdoviruses have been engineered for expression of surface protein genes and antigens. Administration of replicon RNA vectors has resulted in strong immune responses and generation of neutralizing antibodies in various animal models. Immunization of mice, chicken, pigs and primates with virus-like particles, naked RNA or layered DNA/RNA plasmids has provided protection against challenges with lethal doses of infectious agents and administered tumor cells. Both prophylactic and therapeutic efficacy has been achieved in cancer immunotherapy. Moreover, recombinant particles and replicon RNAs have been encapsulated by liposomes to improve delivery and targeting. Replicon RNA vectors have also been subjected to clinical trials. Overall, immunization with self-replicating RNA viruses provides high transient expression levels of antigens resulting in generation of neutralizing antibody responses and protection against lethal challenges under safe conditions.

show abstract

Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines

Cited by 10 publications

References 31 publications

Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene

Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene

Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya

Replicon RNA Viral Vectors as Vaccines

Contact Info

Product

Resources

About